Do analysts prefer SNYR or SRNE?

Synergy CHC currently has a consensus price target of $6.25, suggesting a potential upside of 2,954.74%. Given Synergy CHC's stronger consensus rating and higher possible upside, research analysts plainly believe Synergy CHC is more favorable than Sorrento Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synergy CHC 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Sorrento Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts recommend SRNE or PPCB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sorrento Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Propanc Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is SRNE or PPCB more profitable?

Sorrento Therapeutics' return on equity of 0.00% beat Propanc Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Sorrento Therapeutics N/A N/A N/A Propanc Biopharma N/A -151.28% -109.53%

Do analysts prefer SRNE or ARTL?

Artelo Biosciences has a consensus price target of $54.00, indicating a potential upside of 3,990.91%. Given Artelo Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Artelo Biosciences is more favorable than Sorrento Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sorrento Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Artelo Biosciences 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Is SRNE or ARTL more profitable?

Sorrento Therapeutics' return on equity of 0.00% beat Artelo Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Sorrento Therapeutics N/A N/A N/A Artelo Biosciences N/A -1,600.12% -224.62%

Do analysts rate SRNE or VIVS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sorrento Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 VivoSim Labs 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is VCNX or SRNE more profitable?

Company Net Margins Return on Equity Return on Assets Vaccinex N/A N/A -383.58% Sorrento Therapeutics N/A N/A N/A

Sorrento Therapeutics (SRNE) Competitors

$0.0007 0.00 (-22.22%)

As of 11:49 AM Eastern

Compare

SRNE vs. SNYR, PPCB, ARTL, VIVS, and VCNX

Should you buy Sorrento Therapeutics stock or one of its competitors? MarketBeat compares Sorrento Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Sorrento Therapeutics include Synergy CHC (SNYR), Propanc Biopharma (PPCB), Artelo Biosciences (ARTL), VivoSim Labs (VIVS), and Vaccinex (VCNX). These companies are all part of the "pharmaceutical products" industry.

How does Sorrento Therapeutics compare to Synergy CHC?

Synergy CHC (NASDAQ:SNYR) and Sorrento Therapeutics (NASDAQ:SRNE) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, analyst recommendations, institutional ownership, dividends, valuation and profitability.

0.0% of Sorrento Therapeutics shares are held by institutional investors. 32.9% of Synergy CHC shares are held by company insiders. Comparatively, 2.6% of Sorrento Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Synergy CHC currently has a consensus price target of $6.25, suggesting a potential upside of 2,954.74%. Given Synergy CHC's stronger consensus rating and higher possible upside, research analysts plainly believe Synergy CHC is more favorable than Sorrento Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synergy CHC	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Sorrento Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Sorrento Therapeutics has a net margin of 0.00% compared to Synergy CHC's net margin of -60.02%. Sorrento Therapeutics' return on equity of 0.00% beat Synergy CHC's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Synergy CHC	-60.02%	-19.51%	-30.30%
Sorrento Therapeutics	N/A	N/A	N/A

Synergy CHC has a beta of -0.27, indicating that its stock price is 127% less volatile than the broader market. Comparatively, Sorrento Therapeutics has a beta of 0.17, indicating that its stock price is 83% less volatile than the broader market.

In the previous week, Synergy CHC had 12 more articles in the media than Sorrento Therapeutics. MarketBeat recorded 12 mentions for Synergy CHC and 0 mentions for Sorrento Therapeutics. Sorrento Therapeutics' average media sentiment score of 0.00 beat Synergy CHC's score of -0.47 indicating that Sorrento Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Synergy CHC	Neutral
Sorrento Therapeutics	Neutral

Synergy CHC has higher earnings, but lower revenue than Sorrento Therapeutics. Synergy CHC is trading at a lower price-to-earnings ratio than Sorrento Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synergy CHC	$30.38M	0.10	-$12.34M	-$1.40	N/A
Sorrento Therapeutics	$60.32M	0.01	-$572.84M	-$0.43	N/A

Summary

Sorrento Therapeutics beats Synergy CHC on 9 of the 16 factors compared between the two stocks.

How does Sorrento Therapeutics compare to Propanc Biopharma?

Sorrento Therapeutics (NASDAQ:SRNE) and Propanc Biopharma (NASDAQ:PPCB) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, dividends, earnings, profitability, media sentiment and institutional ownership.

Sorrento Therapeutics has a beta of 0.17, indicating that its share price is 83% less volatile than the broader market. Comparatively, Propanc Biopharma has a beta of 3.48, indicating that its share price is 248% more volatile than the broader market.

0.0% of Sorrento Therapeutics shares are held by institutional investors. 2.6% of Sorrento Therapeutics shares are held by company insiders. Comparatively, 28.5% of Propanc Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Propanc Biopharma has lower revenue, but higher earnings than Sorrento Therapeutics. Propanc Biopharma is trading at a lower price-to-earnings ratio than Sorrento Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sorrento Therapeutics	$60.32M	0.01	-$572.84M	-$0.43	N/A
Propanc Biopharma	N/A	N/A	-$58.92M	-$24.25	N/A

In the previous week, Propanc Biopharma had 7 more articles in the media than Sorrento Therapeutics. MarketBeat recorded 7 mentions for Propanc Biopharma and 0 mentions for Sorrento Therapeutics. Propanc Biopharma's average media sentiment score of 0.80 beat Sorrento Therapeutics' score of 0.00 indicating that Propanc Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Sorrento Therapeutics	Neutral
Propanc Biopharma	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sorrento Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Propanc Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Sorrento Therapeutics' return on equity of 0.00% beat Propanc Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sorrento Therapeutics	N/A	N/A	N/A
Propanc Biopharma	N/A	-151.28%	-109.53%

Summary

Sorrento Therapeutics and Propanc Biopharma tied by winning 6 of the 12 factors compared between the two stocks.

How does Sorrento Therapeutics compare to Artelo Biosciences?

Sorrento Therapeutics (NASDAQ:SRNE) and Artelo Biosciences (NASDAQ:ARTL) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, risk, profitability, media sentiment, valuation, analyst recommendations and earnings.

Artelo Biosciences has a consensus price target of $54.00, indicating a potential upside of 3,990.91%. Given Artelo Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Artelo Biosciences is more favorable than Sorrento Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sorrento Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Artelo Biosciences	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Artelo Biosciences has lower revenue, but higher earnings than Sorrento Therapeutics. Artelo Biosciences is trading at a lower price-to-earnings ratio than Sorrento Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sorrento Therapeutics	$60.32M	0.01	-$572.84M	-$0.43	N/A
Artelo Biosciences	N/A	N/A	-$12.88M	-$32.74	N/A

0.0% of Sorrento Therapeutics shares are owned by institutional investors. Comparatively, 0.9% of Artelo Biosciences shares are owned by institutional investors. 2.6% of Sorrento Therapeutics shares are owned by company insiders. Comparatively, 3.2% of Artelo Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Artelo Biosciences had 4 more articles in the media than Sorrento Therapeutics. MarketBeat recorded 4 mentions for Artelo Biosciences and 0 mentions for Sorrento Therapeutics. Artelo Biosciences' average media sentiment score of 0.72 beat Sorrento Therapeutics' score of 0.00 indicating that Artelo Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Sorrento Therapeutics	Neutral
Artelo Biosciences	Positive

Sorrento Therapeutics has a beta of 0.17, meaning that its share price is 83% less volatile than the broader market. Comparatively, Artelo Biosciences has a beta of -0.13, meaning that its share price is 113% less volatile than the broader market.

Sorrento Therapeutics' return on equity of 0.00% beat Artelo Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sorrento Therapeutics	N/A	N/A	N/A
Artelo Biosciences	N/A	-1,600.12%	-224.62%

Summary

Artelo Biosciences beats Sorrento Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Sorrento Therapeutics compare to VivoSim Labs?

Sorrento Therapeutics (NASDAQ:SRNE) and VivoSim Labs (NASDAQ:VIVS) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, risk and dividends.

VivoSim Labs has lower revenue, but higher earnings than Sorrento Therapeutics. VivoSim Labs is trading at a lower price-to-earnings ratio than Sorrento Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sorrento Therapeutics	$60.32M	0.01	-$572.84M	-$0.43	N/A
VivoSim Labs	$140K	22.09	-$2.48M	-$3.15	N/A

Sorrento Therapeutics has a beta of 0.17, indicating that its stock price is 83% less volatile than the broader market. Comparatively, VivoSim Labs has a beta of 1.38, indicating that its stock price is 38% more volatile than the broader market.

In the previous week, VivoSim Labs had 2 more articles in the media than Sorrento Therapeutics. MarketBeat recorded 2 mentions for VivoSim Labs and 0 mentions for Sorrento Therapeutics. VivoSim Labs' average media sentiment score of 1.28 beat Sorrento Therapeutics' score of 0.00 indicating that VivoSim Labs is being referred to more favorably in the news media.

Company	Overall Sentiment
Sorrento Therapeutics	Neutral
VivoSim Labs	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sorrento Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
VivoSim Labs	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Sorrento Therapeutics has a net margin of 0.00% compared to VivoSim Labs' net margin of -861.27%. Sorrento Therapeutics' return on equity of 0.00% beat VivoSim Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sorrento Therapeutics	N/A	N/A	N/A
VivoSim Labs	-861.27%	-15.51%	-11.31%

0.0% of Sorrento Therapeutics shares are owned by institutional investors. Comparatively, 8.2% of VivoSim Labs shares are owned by institutional investors. 2.6% of Sorrento Therapeutics shares are owned by company insiders. Comparatively, 2.5% of VivoSim Labs shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Sorrento Therapeutics and VivoSim Labs tied by winning 7 of the 14 factors compared between the two stocks.

How does Sorrento Therapeutics compare to Vaccinex?

Vaccinex (NASDAQ:VCNX) and Sorrento Therapeutics (NASDAQ:SRNE) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and dividends.

50.1% of Vaccinex shares are owned by institutional investors. Comparatively, 0.0% of Sorrento Therapeutics shares are owned by institutional investors. 51.5% of Vaccinex shares are owned by company insiders. Comparatively, 2.6% of Sorrento Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Vaccinex has higher earnings, but lower revenue than Sorrento Therapeutics. Vaccinex is trading at a lower price-to-earnings ratio than Sorrento Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaccinex	$388K	7.04	-$20.25M	-$48.27	N/A
Sorrento Therapeutics	$60.32M	0.01	-$572.84M	-$0.43	N/A

In the previous week, Vaccinex's average media sentiment score of 0.00 equaled Sorrento Therapeutics'average media sentiment score.

Company	Overall Sentiment
Vaccinex	Neutral
Sorrento Therapeutics	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Vaccinex	N/A	N/A	-383.58%
Sorrento Therapeutics	N/A	N/A	N/A

Vaccinex has a beta of 1.1, suggesting that its stock price is 10% more volatile than the broader market. Comparatively, Sorrento Therapeutics has a beta of 0.17, suggesting that its stock price is 83% less volatile than the broader market.

Summary

Vaccinex beats Sorrento Therapeutics on 5 of the 9 factors compared between the two stocks.

Get Sorrento Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SRNE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SRNE vs. The Competition

Export

Metric	Sorrento Therapeutics	Biological Products Industry	Medical Sector	NASDAQ Exchange
Market Cap	$386K	$349.08M	$6.50B	$12.37B
Dividend Yield	N/A	N/A	2.67%	5.66%
P/E Ratio	0.00	N/A	24.01	24.71
Price / Sales	0.01	171.60	540.55	165.59
Price / Cash	N/A	22.44	27.48	37.92
Price / Book	N/A	4.76	10.55	6.85
Net Income	-$572.84M	-$141.03M	$3.56B	$337.45M
7 Day Performance	N/A	0.80%	1.54%	2.70%
1 Month Performance	N/A	-4.56%	2.48%	4.60%
1 Year Performance	N/A	56.83%	26.49%	32.81%

Sorrento Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SRNE Sorrento Therapeutics	N/A	$0.00 -22.2%	N/A	-57.1%	$386K	$60.32M	N/A	800	Gap Up
SNYR Synergy CHC	2.1413 of 5 stars	$0.20 -5.4%	$6.25 +3,077.4%	-90.6%	$3.14M	$30.38M	N/A	40	News Coverage Analyst Revision
PPCB Propanc Biopharma	1.1822 of 5 stars	$1.38 +0.7%	N/A	-98.9%	$3.12M	N/A	N/A	1	News Coverage Buyback Announcement
ARTL Artelo Biosciences	1.6604 of 5 stars	$1.33 flat	$54.00 +3,960.2%	-93.7%	$3.10M	N/A	N/A	5	Gap Down
VIVS VivoSim Labs	1.43 of 5 stars	$1.19 flat	N/A	-29.2%	$3.10M	$140K	N/A	20	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SRNE) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sorrento Therapeutics (SRNE) Competitors

SRNE vs. SNYR, PPCB, ARTL, VIVS, and VCNX

How does Sorrento Therapeutics compare to Synergy CHC?

Summary

How does Sorrento Therapeutics compare to Propanc Biopharma?

Summary

How does Sorrento Therapeutics compare to Artelo Biosciences?

Summary

How does Sorrento Therapeutics compare to VivoSim Labs?

Summary

How does Sorrento Therapeutics compare to Vaccinex?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SRNE vs. The Competition

Sorrento Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sorrento Therapeutics (SRNE) Competitors

SRNE vs. SNYR, PPCB, ARTL, VIVS, and VCNX

How does Sorrento Therapeutics compare to Synergy CHC?

Do insiders & institutionals hold more shares of SNYR or SRNE?

Do analysts prefer SNYR or SRNE?

Is SNYR or SRNE more profitable?

Which has more risk & volatility, SNYR or SRNE?

Does the media refer more to SNYR or SRNE?

Which has higher earnings and valuation, SNYR or SRNE?

Summary

How does Sorrento Therapeutics compare to Propanc Biopharma?

Which has more risk & volatility, SRNE or PPCB?

Do insiders and institutionals have more ownership in SRNE or PPCB?

Which has better valuation & earnings, SRNE or PPCB?

Does the media prefer SRNE or PPCB?

Do analysts recommend SRNE or PPCB?

Is SRNE or PPCB more profitable?

Summary

How does Sorrento Therapeutics compare to Artelo Biosciences?

Do analysts prefer SRNE or ARTL?

Which has higher valuation and earnings, SRNE or ARTL?

Do insiders & institutionals believe in SRNE or ARTL?

Does the media prefer SRNE or ARTL?

Which has more volatility & risk, SRNE or ARTL?

Is SRNE or ARTL more profitable?

Summary

How does Sorrento Therapeutics compare to VivoSim Labs?

Which has higher earnings & valuation, SRNE or VIVS?

Which has more volatility & risk, SRNE or VIVS?

Does the media refer more to SRNE or VIVS?

Do analysts rate SRNE or VIVS?

Is SRNE or VIVS more profitable?

Do insiders and institutionals have more ownership in SRNE or VIVS?

Summary

How does Sorrento Therapeutics compare to Vaccinex?

Do insiders & institutionals have more ownership in VCNX or SRNE?

Which has better earnings & valuation, VCNX or SRNE?

Does the media favor VCNX or SRNE?

Is VCNX or SRNE more profitable?

Which has more volatility and risk, VCNX or SRNE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SRNE vs. The Competition

Sorrento Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools